the aorta itself can change with age and remodel, and eventually develop aneurysms in its thoracic or abdominal part. This issue of the journal is devoted to the aortic valve and in particular the management of patients after valve implantation, as well as the treatment of abdominal aortic aneurysms, a common and potentially fatal disease particularly in male smokers. 3, 4 This focus issue begins, however, with a timely Clinical Review article on a slightly different topic, i.e. 'Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives' by Chris Semsarian from the Royal Prince Alfred Hospital in Camperdown, NSW, Australia. 5 Sudden cardiac death of a young, apparently fit and healthy individual is a particularly devastating event for the patient's family and treating physicians alike. While coronary artery disease and acute myocardial infarction are the most common causes of sudden cardiac death in older populations, genetic cardiac conditions comprise a substantial proportion of such cases in those aged ≤40 years. These include arrhythmogenic disorders such as the long QT syndromes, and inherited cardiomyopathies, namely hypertrophic cardiomyopathy. In up to 30% of young sudden cardiac death, no apparent cause of death can be found, i.e. so-called 'autopsy negative' or 'sudden arrhythmic death syndrome'. Management of families following sudden cardiac death begins with a concerted effort to identify the cause of death in the decedent, based on either pre-morbid clinical details or the pathological findings at post-mortem. Where no cause can be found, genetic testing of DNA extracted from post-mortem blood, i.e. the molecular autopsy, may identify underlying mechanisms in up to 30% of cases. The authors stress the fact that optimal care of families with a sudden cardiac death amongst their loved ones requires dedicated and appropriately trained staff in a multidisciplinary cardiac genetic clinic. 5 The first paper of this issue is dedicated to the natural history of transcatheter aortic valve implantation (TAVI) valves after implantation. In the ageing Western population, aortic stenosis has become increasingly common, particularly in the elderly. 2, 6 Due to the high operative risk in these frequently frail patients, TAVI or transcatheter aortic valve replacement (TAVR; for our US readers) has been developed. 7 With appropriate pre-operative assessment including sophisticated imaging, 8 modern valves, and experienced operators, the results have become increasingly better and peri-interventional mortality has declined. 9 As a result, the European Society of Cardiology (ESC) Guidelines on valvular heart disease 10 assigned TAVI a I B-C recommendation in patients selected by an experienced Heart Team. This has stirred enthusiasm to use this minimally invasive technique also in patients of lesser age and in those of medium operative risk. The true longevity of these bioprosthetic valves, however, remains unknown. Thus, the first clinical research paper entitled 'Transcatheter heart valve failure: a systematic review' by Nicolo Piazza from the McGill University Health Centre in Montreal, Canada, 11 accompanied by an Editorial by Jan-Malte Sinning from the Heart Center Bonn, Germany 12 serves an unmet need. The paper provides a comprehensive description of transcatheter heart valve failure. Between December 2002 and March 2014, a total of 70 publications reported 87 individual cases of TAVI failure. Similar to surgical bioprosthetic heart valve failure, 34 cases of prosthetic valve endocarditis with a similar microbiological profile to surgical cases, 13 structural valve failures, and 15 valve thromboses were noted. Structural valve failure occurred mostly due to leaflet calcification and was predominantly treated in two-thirds of cases by a redo procedure. Valve thrombosis occurred at a mean 9 months post-implantation and was successfully treated by prolonged anticoagulation in three-quarters of the cases. Furthermore, two novel causes of valve failure were identified, i.e. 18 cases of late valve embolization mandating surgery in 80%, and 7 cases of valve compression following cardiopulmonary resuscitation. Potential risk factors for late valve embolization appear to include low prosthesis implantation, valve undersizing, or underexpansion, and bicuspid and non-calcified anatomy. The authors conclude that transaortic valves are susceptible to failures noted already with surgical bioprostheses, as well as unique causes of failure specific to their specific design. TAVI bioprostheses compression and late embolization represent complications previously unreported. Unlike TAVI bioprostheses, surgically implanted mechanical valves do require lifelong anticoagulation with vitamin K antagonists. 13 Surprisingly, novel oral anticoagulants do not work in this indication. 14 The second paper 'Telemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants' by Armin Zittermann from the Heart Center North-Rhine Westfalia in Germany 15 therefore addresses this important topic. The authors studied the efficacy Of note, the ESC recently published their guidelines on that issue. 18 An important development in the management of patients is the introduction of endovascular aneurysm repair (EVAR), which is much less invasive for patients than the classical surgical approach. 19 Whether a patient with a ruptured abdominal aortic aneur- The editors hope that this issue of the European Heart Journal will be received with interest by its readers.
